Cerebrospinal fluid proteomic patterns discriminate Parkinson's disease and multiple system atrophy

The differential diagnosis of Parkinson's disease and multiple system atrophy can be challenging, especially in the early stages of the diseases. We developed a proteomic profiling strategy for parkinsonian diseases using mass spectrometry analysis for magnetic‐bead‐based enrichment of cerebrospinal fluid peptides/proteins and subsequent multivariate statistical analysis. Cerebrospinal fluid was obtained from 37 patients diagnosed with Parkinson's disease, 32 patients diagnosed with multiple system atrophy, and 26 patients diagnosed with other neurological diseases as controls. The samples were from the first cohort and the second cohort. Cerebrospinal fluid peptides/proteins were purified with C8 magnetic beads, and spectra were obtained by matrix‐assisted laser desorption ionization time‐of‐flight mass spectrometry. Principal component analysis and support vector machine methods are used to reduce dimension of the data and select features to classify diseases. Cerebrospinal fluid proteomic profiles of Parkinson's disease, multiple system atrophy, and control were differentiated from each other by principal component analysis. By building a support vector machine classifier, 3 groups were classified effectively with good cross‐validation accuracy. The model accuracy was well preserved for both cases, training by the first cohort and validated by the second cohort and vice versa. Receiver operating characteristics proved that the peak of m/z 6250 was the most important to differentiate multiple system atrophy from Parkinson's disease, especially in the early stages of the disease. A proteomic pattern classification method can increase the accuracy of clinical diagnosis of Parkinson's disease and multiple system atrophy, especially in the early stages. © 2012 Movement Disorder Society

[1]  G. Wenning,et al.  Multiple system atrophy: an update , 2009, The Lancet Neurology.

[2]  Ralf Ketterlinus,et al.  Fishing for biomarkers: analyzing mass spectrometry data with the new ClinProTools software. , 2005, BioTechniques.

[3]  T. Tokuda,et al.  Decreased α-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson’s disease. , 2006 .

[4]  W. F. Abdo,et al.  Cerebrospinal fluid analysis differentiates multiple system atrophy from Parkinson's disease , 2004, Movement disorders : official journal of the Movement Disorder Society.

[5]  K. Tashiro,et al.  Applying Magnetic Bead Separation / MALDI-TOF Mass Spectrometry to Human Tear Fluid Proteome Analysis , 2008 .

[6]  Brit Mollenhauer,et al.  α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study , 2011, The Lancet Neurology.

[7]  A. Fagan,et al.  Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. , 2007, Archives of neurology.

[8]  Aneeka M Hancock,et al.  DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. , 2010, Brain : a journal of neurology.

[9]  J. Kassubek,et al.  Neurofilament heavy‐chain NfHSMI35 in cerebrospinal fluid supports the differential diagnosis of Parkinsonian syndromes , 2006, Movement disorders : official journal of the Movement Disorder Society.

[10]  T. Tokuda,et al.  Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. , 2006, Biochemical and biophysical research communications.

[11]  Klaus Seppi,et al.  Proposed neuroimaging criteria for the diagnosis of multiple system atrophy , 2009, Movement disorders : official journal of the Movement Disorder Society.

[12]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.

[13]  Stefano Ferrero,et al.  Human urine biomarkers of renal cell carcinoma evaluated by ClinProt , 2008, Proteomics. Clinical applications.

[14]  小森 美華,et al.  Proteomic pattern analysis discriminates among multiple sclerosis-related disorders , 2012 .

[15]  K. Helle The granin family of uniquely acidic proteins of the diffuse neuroendocrine system: comparative and functional aspects , 2004, Biological reviews of the Cambridge Philosophical Society.

[16]  K. Blennow,et al.  Proteomic profiling of cerebrospinal fluid in parkinsonian disorders. , 2010, Parkinsonism & related disorders.

[17]  Yu Wang,et al.  Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression , 2011, Annals of neurology.

[18]  P Sandroni,et al.  Second consensus statement on the diagnosis of multiple system atrophy , 2008, Neurology.

[19]  Gordana Ivosev,et al.  Dimensionality reduction and visualization in principal component analysis. , 2008, Analytical chemistry.

[20]  Jing Zhang,et al.  CSF multianalyte profile distinguishes Alzheimer and Parkinson diseases. , 2008, American journal of clinical pathology.

[21]  J. Hughes,et al.  Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. , 1992, Journal of neurology, neurosurgery, and psychiatry.

[22]  Yan Liu,et al.  Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. , 2006, Journal of Alzheimer's disease : JAD.

[23]  H. Groenewegen,et al.  Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: A pathogenetically based approach , 2010, Neurobiology of Disease.